Efficacy of NK1 receptor antagonist (aprepitant) in the cancer chemotherapies for hematologic malignancies.
Phase 2
Recruiting
- Conditions
- hematologic malignancies
- Registration Number
- JPRN-UMIN000006690
- Lead Sponsor
- Kagoshima University Hospital, division of Hematology and Immunology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
patients unable to answer the questions about efficacy of aprepitant
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method